title: Prospective randomized double blind placebo-controlled evaluation of azithromycin for treatment of cat-scratch disease.
abstract: OBJECTIVE
  To determine the efficacy of azithromycin in the treatment of patients with typical cat-scratch disease.
  
  
  METHODS
  Prospective, randomized, double blind, placebo-controlled clinical trial.
  
  
  METHODS
  Large military medical center and its referring clinics.
  
  
  METHODS
  Active duty military members and their dependents with laboratory-confirmed, clinically typical cat-scratch disease.
  
  
  METHODS
  Study participants assigned by randomization to treatment with oral azithromycin or placebo for 5 days.
  
  
  METHODS
  Lymph node volume was calculated using three dimensional ultrasonography at entry and at weekly intervals. The ultrasonographer was blinded to the treatment groups. Endpoint evaluations were predetermined as time in days to 80% resolution of the initial total lymph node volume.
  
  
  RESULTS
  Demographic and clinical data showed that the azithromycin and placebo treatment groups were comparable at entry although the placebo group tended to be older. Eighty percent decrease of initial lymph node volume was documented in 7 of 14 azithromycin-treated patients compared with 1 of 15 placebo-treated controls during the first 30 days of observation (P = 0.026). After 30 days there was no significant difference in rate or degree of resolution between the two groups.
  
  
  CONCLUSIONS
  Treatment of patients with typical cat-scratch disease with oral azithromycin for five days affords significant clinical benefit as measured by total decrease in lymph node volume within the first month of treatment.
authors.affiliation: Department of Pediatrics, Tripler Army Medical Center, Honolulu, HI 96859-5000, USA. jimbass@pixinet.com
authors.forename: J W
authors.initials: JW
authors.lastname: Bass
authors.forename: B C
authors.initials: BC
authors.lastname: Freitas
authors.forename: A D
authors.initials: AD
authors.lastname: Freitas
authors.forename: C L
authors.initials: CL
authors.lastname: Sisler
authors.forename: D S
authors.initials: DS
authors.lastname: Chan
authors.forename: J M
authors.initials: JM
authors.lastname: Vincent
authors.forename: D A
authors.initials: DA
authors.lastname: Person
authors.forename: J R
authors.initials: JR
authors.lastname: Claybaugh
authors.forename: R R
authors.initials: RR
authors.lastname: Wittler
authors.forename: M E
authors.initials: ME
authors.lastname: Weisse
authors.forename: R L
authors.initials: RL
authors.lastname: Regnery
authors.forename: L N
authors.initials: LN
authors.lastname: Slater
mesh_terms: D000293:Adolescent; D000328:Adult; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D017963:Azithromycin / Q000627:therapeutic use*; D018416:Bartonella henselae; D002372:Cat-Scratch Disease / Q000188:drug therapy*; D002648:Child; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D016015:Logistic Models; D008198:Lymph Nodes / Q000000981:diagnostic imaging; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D014463:Ultrasonography
chemical_list: D000900:Anti-Bacterial Agents; D017963:Azithromycin